CN107595758A - A kind of amnion emulsion preparation method, amnion emulsion glue connection facial mask and preparation method thereof - Google Patents
A kind of amnion emulsion preparation method, amnion emulsion glue connection facial mask and preparation method thereof Download PDFInfo
- Publication number
- CN107595758A CN107595758A CN201711088787.1A CN201711088787A CN107595758A CN 107595758 A CN107595758 A CN 107595758A CN 201711088787 A CN201711088787 A CN 201711088787A CN 107595758 A CN107595758 A CN 107595758A
- Authority
- CN
- China
- Prior art keywords
- amnion
- emulsion
- facial mask
- glue
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001691 amnion Anatomy 0.000 title claims abstract description 193
- 239000000839 emulsion Substances 0.000 title claims abstract description 114
- 230000001815 facial effect Effects 0.000 title claims abstract description 90
- 239000003292 glue Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 210000001519 tissue Anatomy 0.000 claims abstract description 34
- 108010073385 Fibrin Proteins 0.000 claims abstract description 24
- 102000009123 Fibrin Human genes 0.000 claims abstract description 24
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229950003499 fibrin Drugs 0.000 claims abstract description 24
- 239000012528 membrane Substances 0.000 claims abstract description 22
- 210000004379 membrane Anatomy 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 41
- 210000002826 placenta Anatomy 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 241001494479 Pecora Species 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 12
- 238000007689 inspection Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000007711 solidification Methods 0.000 claims description 8
- 230000008023 solidification Effects 0.000 claims description 8
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 229960004072 thrombin Drugs 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003862 health status Effects 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
- 229940033663 thimerosal Drugs 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 13
- 238000004140 cleaning Methods 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000003020 moisturizing effect Effects 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 238000010008 shearing Methods 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 231100000241 scar Toxicity 0.000 abstract description 2
- 239000011800 void material Substances 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000001151 other effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000005059 placental tissue Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000282994 Cervidae Species 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 235000019687 Lamb Nutrition 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000006385 ozonation reaction Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 210000003425 amniotic epithelial cell Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000010148 water-pollination Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 241001136169 Komagataeibacter xylinus Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000011176 biofiber Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 108010020919 eel intestinal pentapeptide Proteins 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002281 placental hormone Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
The present invention relates to amnion emulsion glue connection facial mask and preparation method thereof, tissue emulsion and fibrin glued membrane is respectively prepared in animal amnion and animal blood, then the two glue is unified into and joins facial mask for amnion emulsion glue；By the way that natural amnion is processed into amnion emulsion, the complete nutrients matter in amnion is set to be discharged with active component, after note thing glue connection being carried with Fibrin Glue, due to the amplification effect of Fibrin Glue, add the expression of Ingredient, the intrinsic biological activity of amnion emulsion is exaggerated, facial mask is produced nutrition, moisturizing, whitening, scar of dispelling, cleaning and other effects；The invention further relates to the preparation method of amnion emulsion, amnion is first carried out tissue homogenate, then cell degradation is carried out using low-temperature ultrahigh-pressure continuous flow cell disintegrating machine, utilize super-pressure energy caused by equipment hydraulic power, material is set to pass through slit abrupt release, in the presence of shearing, void effect, material is set to reach shearing, homogeneous, scattered, emulsifying effectiveness.
Description
Technical field
The present invention relates to cosmetics and skincare product and the technical field of cosmetics and skincare product preparation method, more particularly to a kind of amnion breast
Liquid and preparation method thereof, amnion emulsion glue connection facial mask and preparation method thereof.
Background technology
Facial mask is widely loved by consumers because its is easy to use, effect is good as a kind of common cosmetics, from 2013
Since year, facial mask has turned into the first choice of popular cosmetics consumption；The facial mask sold in the market can be divided into battalion by effect
Support facial mask, cleaning pack, moisturizing (moisturizing) facial mask, cleawhite pack, nourishing facial mask, anti-wrinkle face mask, freckle-removing mask, reparation facial mask 8
Major class；Classify by the material of facial mask, there is non-woven fabrics, silk, biological fiber, mud film etc.；The kind of domestic various facial masks reaches hundreds of
As many as kind.
Shown according to AC Nelson's portion market survey reports, 2012, Chinese facial mask market sale scale is up to 78.5
Hundred million yuan, increase by 33% on a year-on-year basis, at the same time, facial mask is 17.7% in Chinese existing market permeability, and Cosmetic Market permeates
Rate 83.3%.Mounted facial mask (face note film) product will progressively grow as independence, a huge market in China.
As skin type product that is quick, effectively changing skin condition, development in recent years shows to be skyrocketed through facial mask
Trend；Its focus is：(1) advocate and develop biological mask product, reduce or eliminate chemical composition facial mask.Biological fiber face at present
Film is domestic only biological species mask product, and it is advantageous in that：1. biological facial mask has good hydrophily, oxygen flow
Property, adhesiveness；2. there is good note right with skin；3., not damaged non-stimulated to skin.2007, first invisible face pack
It is born, is that will be originally intended to medical field processing to scald that special bionic dermis --- " stealthy film " develops into current beauty industry face
The top material of film；Invisible face pack meets human face ergonomic designs, and superpower compactness can retain and supplement to greatest extent
The facial mask of moisture and nutrient needed for skin, invisible face pack are the natural materials for copying human body skin epidermal tissue, and support is highly concentrated
Essence is spent, whole face can be affixed on, be bonded completely with skin, and there is good permeability, ensures the eupnea of skin,
Obstruct the pollutant in air.(2) face-mask material and mask product that exploitation is natural, green is nonirritant.Biofibre facial mask
It is the corpus fibrosum made of acetobacter xylinum spontaneous fermentation, there is the dermatoid function of class；The facial mask quality is very soft, elasticity
Good, toughness is strong, non-stimulated free from extraneous odour, is not easy to grow bacterium, without fluorescent material, easily cleaning, is that pure natural health environment-friendly is used
Product；Due to the characteristic do not repelled by human body, being used as cardiovascular reparation in medical field and being used with artificial skin；In view of
These characteristics, biology cellulose facial mask are extensively favored in market.(3) multi-functional, versatility.The function that facial mask is carried is many
It is more：Nutrition, whitening, cleaning, moisturizing, whitening, nourishing, it is crease-resistant, repair etc., so, a product possessed function it is more more more
Good, this requires mask product to have multi-functional and versatility, so as to meet the growing requirement of consumers in general.
Amnion is a kind of important feature of numerous mammalian placentas, for a kind of transparent, flexible, impassivity, blood vessel, leaching
The natural biological film of hand shaft distribution, its thickness about 0.02~0.05mm.Amnion tissue it is antigenic extremely low, do not cause foreign matter anti-
Should, because the epithelium layer of amnion does not express HLA (HLA-II), cause it to lack immunogenicity.
Amnion convenient material drawing, wide material sources, cost is low, extensively should in clinical medicine as a kind of biology reconstruction biomaterialses
With amnion, which has, to be suppressed inflammation, reduces fibrosis, reduce the biological actions such as pain, and substantial amounts of modern study illustrates, amnion
In contain tens of kinds of bioactive substances, produce extensive biological function.Contain a variety of collagens in the matrix components of amnion
(Collagen), integrin (Integrin), laminin (LN) and laminated body (LB) etc., they, which have, maintains epidermis complete
Property, Epithelial Cell Apoptosis is prevented, promotion epithelial cell is divided a word with a hyphen at the end of a line and differentiation.In amnion containing a variety of growth factors such as：Epidermis
Growth factor (EGF), TGF (TGF), keratinocyte growth factor (KGF), HGF (HGF) and
Basic fibroblast growth factor (bFGF) etc., overview is got up, and the comprehensive function of these cell factors can be summarized as 3 classes：⑴
Promote epithelial cell proliferation and differentiation, numerous cell factors and biology enzyme promote epitheliosis, while also improve epithelium
Tissue metabolism, so as to maintain the complete of epithelium with stably；(2) promote collagen deposition and tissue repair, polytropism cell factor to have
Stimulate the effect of various target cell growths, moreover it is possible to induce epithelial cell to form monolayer colonies, promotion organization reparation；(3) wound is accelerated
Healing, suppress fibrosis, produce antiscarring effect, its mechanism is some cell factors by suppressing transforming growth factor β (TGF-
Synthesis β), so as to suppress the activity of fibroblast, reduce the formation of scar.In addition, also contain a variety of enzymes in amnion,
That discloses mainly has three classes：One kind is matrix metalloproteinase (MMP) and Expression of TIMP (TIMP), there is report
Think that this fermentoid plays a significant role during anti-neovascularization and interstitial fibrosis in road；Another kind of is the suppression of multiple protein enzyme
The factor processed is (such as：α -1 antitrypsins, α -2 ACTs etc.), anti-inflammatory factors (such as：Interleukin-1 receptor antagonist
IL-1Ra) and the anti-angiogenetic therapy factor (such as：Endostatin precursor protein EIPP, THBS1 TSP-1) etc., these
The factor plays antiinflammatory action, angiogenesis inhibiting by suppressing corresponding protease.3rd class be neurotrophic factor (such as：
Nerve growth trophic factors NGF, BDNF BDNF etc.), there is very strong neuroprotection.
Amnion is membrane structure most thick in body, generally by 5 layer tissue structures：Epithelium layer, basilar memebrane, compacted zone,
Fibrocyte layer and spongy layer.Epithelium layer contains amniotic epithelial cells and lived by the various biologies of amniotic epithelial cells secretion
Sexual element, epithelial cell synthesize and secrete matrix component, maintain the stability of film.Basilar memebrane is based on reticular fibre, rich in tool
The proteoglycan of heparin sulfate, it is the institutional framework that barrier action is played in amnion.Compacted zone is thin and compact, plays support and filtration
Effect.
In addition, natural amnion also has certain anti-infection ability, someone (Uberti etc., 2011) report, macrophage
Kill the ability of Escherichia coli and the concentration correlation of amnion source property cell factor solution.
A variety of characteristics of amnion show that it is technically feasible that animal (sheep, goat, deer) amnion, which is used as mankind's facial mask,
, and overcome using human amniotic membrane and caused ethics and the question of morality：First, animal (sheep, goat, deer) is amnion-derived
Extensively, cost is cheap；Secondly be not present because of interspecific difference and caused by rejection, and its bigger biological effect of interspecific difference
Better；3rd, domestic and international substantial amounts of Goat Placenta product (such as various placental hormone, freeze-dried powder, capsule, oral liquid and externally applied products)
It is used for the mankind by way of injection, oral, external application, its security, validity do not hold query, but currently without prior art
Using preparing raw material of the amnion as facial mask.
The content of the invention
It is an object of the invention in view of the above-mentioned problems, providing a kind of amnion emulsion preparation method, amnion emulsion glue connection face
Film and preparation method thereof, skin, biological facial mask single varieties, effect list are stimulated and damage to solve existing chemical composition facial mask
One, the technical problems such as amnion purposes is less.
Technical problem solved by the invention can take following scheme to realize：A kind of amnion emulsion glue joins facial mask, its
It is characterised by：The facial mask includes facial mask load patch thing and glue connection made of fibrin glued membrane and solidified in facial mask load patch thing
On amnion emulsion, the amnion emulsion be animal placenta amnion be made tissue homogenate, by it is described tissue homogenate further drop
Solution filters the tissue emulsion formed afterwards.
Above-mentioned amnion emulsion glue connection facial mask：The tissue homogenate is made up of tissue refiner, group when making tissue homogenate
Knit rotating speed >=12000rpm of refiner, the volume ratio of amnion and water for injection is 1：7 to 1：11；Temperature environment is 15~20
℃。
Above-mentioned amnion emulsion glue connection facial mask：It is described to be degraded to the amnion cell that organized using biomixer in being homogenized
Crushed.
Above-mentioned amnion emulsion glue connection facial mask：The biomixer is low-temperature ultrahigh-pressure continuous flow cell disintegrating machine, institute
State the intensity of pressure >=200Mpa of biomixer, bath temperature is 4~8 DEG C, treating capacity：5~10L/h.
Above-mentioned amnion emulsion glue connection facial mask：Described be filtered into is filtered with 0.22 μm~0.50 μm filter membrane.
Above-mentioned amnion emulsion glue connection facial mask：It is described to be cured as putting the amnion emulsion with Fibrin Glue film composite
Solidify more than 30 minutes under 15~20 DEG C of temperature conditionss.
Above-mentioned amnion emulsion glue connection facial mask：The fibrin glued membrane by mammalian fibrinogen solution and
Thrombin solution mixing, solidification are made.
Above-mentioned amnion emulsion glue connection facial mask：Low peptide content >=1mg/ml of the amnion emulsion, the amnion emulsion
Free aminoacid content >=2mg/ml, the pH value of the amnion emulsion is 5.0~7.0.
A kind of method for being used to prepare above-mentioned amnion emulsion glue connection facial mask, it is characterised in that：Methods described includes as follows
Step：(1) amnion emulsion is prepared：Specifically include following preparation process：(a) animal health inspection：Check, assess placental donor work
The health status of body, select healthy donors；(b) placenta is collected and cleaned：The placenta of selected healthy donors is collected, and to receiving
The placenta taken is cleaned；(c) amnion separation and processing：Amnion is separated from once purged placenta, by separated sheep
Film is shredded and cleaned；(d) amnion sterilizes：The amnion after shredding is sterilized using thimerosal；(e) prepared by amnion emulsion：Will be through
Amnion after sterilization is made tissue using tissue refiner and is homogenized, and tissue is homogenized and carries out clasmatosis, is handled through clasmatosis
It is filtered again afterwards to form amnion emulsion；(2) prepare facial mask and carry patch thing：Solution fibrin original freeze-dried powder and fibrin ferment freeze respectively
Powder, fibrinogen solution and thrombin solution is made, then fibrinogen solution and thrombin solution are uniformly mixed, mix
Fibrin glued membrane is formed after solution solidification afterwards；(3) facial mask is prepared：The amnion emulsion prepared through step (1) is applied to
The fibrin glued membrane surface prepared through step (2), institute will be formed after amnion emulsion and the solidification of Fibrin Glue film composite
State amnion emulsion glue connection facial mask.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：When tissue homogenate is made in the step (e), group
Knit rotating speed >=12000rpm of refiner, the volume ratio of amnion and water for injection is 1：7 to 1：11；Temperature environment is 15~20
℃。
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：The clasmatosis in the step (e)
Amnion tissue homogenate addition low-temperature ultrahigh-pressure continuous flow cell disintegrating machine is degraded in journey, crushes amnion cell, institute
State the intensity of pressure >=200Mpa of biomixer, bath temperature is 4~8 DEG C, treating capacity：5~10L/h.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：Use is filtered into described in the step (e)
0.22 μm~0.50 μm filter membrane is filtered.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：It is described to be cured as the amnion emulsion and fiber egg
White glue film composite, which is placed under 15~20 DEG C of temperature conditionss, to be solidified more than 30 minutes.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：Also include step (f) sheep after the step (e)
Film quality of the emulsion is examined：The pH value of inspection amnion emulsion, low peptide content, free aminoacid content, pH value are 5.0~7.0, low peptide
Content >=1mg/ml, free aminoacid content >=2mg/ml are qualified amnion emulsion.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：The low peptide content is detected with Forint phenol method, uses instrument
Device method detects the free aminoacid content.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：To the fibrin of formation in the step (2)
Glued membrane carries out ozonization.
The above-mentioned method for being used to prepare amnion emulsion glue connection facial mask：Described ozonization disappears under 10ppm concentration
60~120min of poison.
A kind of preparation method of amnion emulsion for facial mask, it is characterised in that：Methods described comprises the following steps：(a)
Animal health inspection：The health status of placental donor live body is checked, assessed, selects healthy donors；(b) placenta is collected and cleaned：
The placenta of selected healthy donors is collected, and the placenta to collecting cleans；(c) amnion separation and processing：By amnion from
Separated on once purged placenta, separated amnion is shredded and cleaned；(d) amnion sterilizes：Using thimerosal to through shredding
Amnion sterilization afterwards；(e) prepared by amnion emulsion：Amnion after will be sterilized is made tissue using tissue refiner and is homogenized, to group
Knit homogenate and carry out clasmatosis, the tissue homogenate after clasmatosis forms amnion emulsion after filtering.
The preparation method of the above-mentioned amnion emulsion for facial mask：When tissue homogenate is made in the step (e), tissue
The volume ratio of rotating speed >=12000rpm of refiner, amnion and water for injection is 1：7 to 1：11；Temperature environment is 15~20 DEG C.
The preparation method of the above-mentioned amnion emulsion for facial mask：The clasmatosis process in the step (e)
It is middle that amnion tissue homogenate addition low-temperature ultrahigh-pressure continuous flow cell disintegrating machine is degraded, amnion cell is crushed, it is described
The intensity of pressure >=200Mpa, the bath temperature of biomixer are 4~8 DEG C, treating capacity：5~10L/h.
The preparation method of the above-mentioned amnion emulsion for facial mask：It is filtered into described in the step (e) with 0.22 μ
M~0.50 μm filter membrane is filtered.
The preparation method of the above-mentioned amnion emulsion for facial mask：It is described to be cured as the amnion emulsion and fibrin
Glued membrane complex, which is placed under 15~20 DEG C of temperature conditionss, to be solidified more than 30 minutes.
The preparation method of the above-mentioned amnion emulsion for facial mask：Also include step (f) amnion after the step (e)
Quality of the emulsion is examined：The pH value of inspection amnion emulsion, low peptide content, free aminoacid content, pH value are that 5.0~7.0, low peptide contains
Amount >=1mg/ml, free aminoacid content >=2mg/ml are qualified amnion emulsion.
The preparation method of the above-mentioned amnion emulsion for facial mask：The low peptide content is detected with Forint phenol method, uses instrument
Method detects the free aminoacid content.
The present invention prepares biological facial mask using natural amnion, enriches the species of mask product and function, opens biology
The frontier of facial mask preparation and application；In viviparous animal, the placenta of ruminant has an easily peelable active amnion, and this
Class amnion causes the amnion of separation to carry cotyledon, if preparing facial mask with amnion basement membrane, it is necessary to bundle due to the presence of placenta cotyledon
Leaf is removed, then the amnion duck eye for going after cotyledon to be likely to form is mended, and therefore, adds technical process；Instant invention overcomes this
The deficiency of technique, amnion emulsion is made in amnion, then joins with fibrin glued membrane glue and prepare facial mask.
Amnion emulsion is applied to facial mask made of Fibrin Glue and carries attachment film surface by the present invention, and amnion emulsion glue connection is made
Facial mask；Amnion and Fibrin Glue are natural polymer biomaterial, made of them facial mask it is nontoxic, it is absorbable, can give birth to
Thing is degraded, green non-pollution；Emulsion is made in amnion, its intrinsic nutritional ingredient and active material is fully discharged, significantly improves
Its bioavailability；Load note thing using fibrin glued membrane prepared by animal blood as facial mask, it is fine equally with biogenic
Fibrillarin glued membrane has biological expression effect to the effective ingredient in amnion emulsion, can make the nutritional ingredient in amnion emulsion and work
Property material produce amplification and synergistic effect；Amnion emulsion and Fibrin Glue film combination are close, not stratified, easy to use, enter one
It is right that step adds note；The facial mask formed by amnion emulsion and fibrin glued membrane glue connection has natural oxygen permeability, hydrophily
With tissue blending.
Embodiment
, below will be to embodiment of the present invention to make the object, technical solutions and advantages of the present invention clearly show
It is described in further detail.
Embodiment
The preparation method of amnion emulsion of the present invention：Animal health inspection → placenta, which is collected, to be separated and processes with cleaning → amnion
It is prepared by → amnion sterilization → amnion emulsion；Amnion emulsion glue connection facial mask preparation method be：Fibrin Glue film preparation → amnion
Emulsion coating → temperature control solidification → facial mask finished product.Amnion is obtained with sheep, goat and deer placenta, has wide material sources, cost low
The characteristics of honest and clean, China concentrate superseded bosom lamb ewe to collect 25 × 25cm more than 6,000,000 with every placenta through slaughterhouse every year
Amnion for meter, in theory whole year can produce amnion 375 × 107cm2。
Illustrate below by taking Goat Placenta as an example：
(1) prepared by amnion emulsion
(1) animal health inspection：Antemortem inspection is slaughtered, to obtain healthy Goat Placenta, the health status of donor flock of sheep is carried out
Accurate evaluation, method are assessed according to local " drove health standards " and combination individual sampling observation, confirm donor sheep health.
1. drove health standards primary evaluation standard has following 5：
-- drove Main Production Rerfomance (carcass weight, lambing percentage, lamb survival rate, the rate of animals delivered to the slaughter-house) is not less than location average water
Flat (- 10%)；
-- case fatality rate, mortality and abortion ratio are not higher than local average level (+10%)；
-- there are clear and definite immune programme for children and immune marking system, inoculum density reaches 100%；
-- there is complete drove health control program；
-- there is good animal doctor's security system.
2. individual sampling observation
5-10% is randomly selected according to Group size to wait to butcher sheep only, is checked item by item by following items：Hair have it is matt, can
Whether normal depending on mucous membrane, whether the state of mind, breathing are uniform, and skin whether there is incrustation, asoscope dry and wet condition, whether there is secretion, food
It is intended to whether normal, nutrition condition, body temperature, body surface lymph node etc. is normal, whether defecation is normal.
3. criterion
Drove health standards 5 meet, and 90% qualified of the individual sampling observation including body temperature, that is, it is qualified to be judged to,
Assert flock of sheep health.
(2) placenta is collected and cleaned
1. generally collecting placenta in qualified slaughterhouse, the healthy ewe placenta concentrated and slaughtered is collected in slaughter hall.
2. placenta maturity is with collecting
Ewe is cherished 90~150 days lamb time, and the time of collecting of in vitro placenta is no more than 2 hours, and placenta collects, cleans
Overall process is no more than 2 hours.
3. placenta is collected and cleaned
Placenta is collected under cleaning condition, removes fetus, amniotic fluid, dirt, watery blood, clot etc., is rinsed 3 times with clear water, then use
Sterile saline is washed 2 times.
4. the inspection of placenta
A, placenta quality inspection
Placenta quality standard is pressed, placenta outward appearance, cotyledon plumpness, cotyledon separation number, weight is examined successively, should conform to
Ask.Examine the 20 DEG C of quick-frozen preservations of qualified Placento-, the holding time no more than 6 months to be advisable.The quality standard of placenta is：Newly
Fresh placenta pale red, free from extraneous odour, neoplasm, hurtless measure, discoloration or corruption, soft no tubercle.Cotyledon is full, and diameter >=
1.0cm, parent cotyledon and fetus cotyledon combine intact, 10% of the segregant number of sheets no more than cotyledon sum.The weight of single placenta
Amount should be 500~1000g.
B, placenta pathogenic microorganism laboratory examination of upchecking exclude sheep cloth Lu Shi diseases, tuberculosis, aftosa, Zhi Yuan
The diseases such as body, choamydiae infection, confirm that placenta is qualified.
Cloth Lu Shi diseases：Examined using cavy inocalation method, specific method is：3 batches respectively sample 10g for pregnacy test disk, are cut into bulk
(1 × 1cm), after adding equivalent sterile saline to soak 30min respectively, placenta tissue is taken out, institute's liquid stay shakes up, and respectively takes 1ml
Mix.1.0ml/ are subcutaneously injected only in cavy 3, are cutd open after 3~4 weeks and kill cavy, and such as spleen, liver and kidney, inflammatory necrosis occur small
Focus, and pathogen is found in spleen, lymph node smear, the positive can be judged to.
Tuberculosis：Examined using PShi solid mediums method, specific method is：3 batches respectively sample 10g for pregnacy test disk, are cut into block
Shape (1 × 1cm), after adding equivalent sterile saline to soak 30min respectively, placenta tissue is taken out, institute's liquid stay shakes up, respectively taken
1ml is mixed.It is inoculated on culture medium, room temperature (incubator) is cultivated at least 20 days.If asepsis growth is judged to feminine gender.If have in yellowish-white
Coloured particles shape, drying, the colony growth of Gram-positive, are judged to the positive.
Aftosa：Examined using suckling mouse method, specific method is：3 batches respectively sample 10g for pregnacy test disks, be cut into it is block (1 ×
1cm), after adding equivalent sterile saline to soak 30min respectively, placenta tissue is taken out, institute's liquid stay shakes up, and respectively takes 1ml to mix.
The suckling mouse 4~5 (being no less than 4) of 2~3 ages in days is taken, neck subcutaneous vaccination 0.1ml/ only, Continuous Observation 7 days, is occurred without following
Symptom is simultaneously all good for living for feminine gender.The positive can be judged to by following symptoms occur：Back leg dyskinesia and then paralysis, head can not
Lift, have difficulty in breathing, eventually because cardiac muscle paralysis is dead.
Mycoplasma：By existing《Chinese veterinary pharmacopoeia》Annex is tested, and must not be detected.
Chlamydia：Examined using intraperitoneal mouse inocalation method, specific method is：3 batches respectively sample 10g for pregnacy test disk, are cut into
Block (1 × 1cm), after adding equivalent sterile saline to soak 30min respectively, placenta tissue is taken out, institute's liquid stay shakes up, respectively taken
1ml is mixed.(0.5ml/ is only) is inoculated in intraperitoneal mouse, and such as all strong work can be judged to feminine gender；If animal is inoculated with 7th~10
Interior death, spleen, lung, liver plate coating checking are taken, the positive can be judged to by detecting Chlamydia and thermophilic alkali inclusion body.
(3) amnion separation and processing
1. amnion separation takes placenta, the artificial blunt separation in the gap between amnion and chorion, the sheep of freezen protective
Film should separate amnion after complete thaw, and the amnion after separation is washed 2 times with sterile saline.
2. under amnion processing aseptic condition, amnion is shredded in ice face, 1~2 × 1~2cm of size, then with sterile physiological salt
Washing 2 times.
(4) amnion sterilizes
Amnion block is soaked in 3% toluene-sodium-sulfonchloramide solution, is stirred 1 time, 24 hours totally 4 times within every 6 hours.Sterilization is finished, and uses sieve method
Pull amnion tissue out, washed 3 times with sterile saline, dried.
(5) prepared by amnion emulsion
1. amnion tissue is made tissue using tissue refiner's (rotating speed >=12000rpm) and is homogenized by tissue homogenate, main skill
Art parameter：Amnion：Water for injection volume ratio is 1：9；Temperature：15~20 DEG C.
2. the above-mentioned amnion tissue homogenate of clasmatosis adds low-temperature ultrahigh-pressure continuous flow cell disintegrating machine and carried out further
Degraded, crushes amnion cell, discharges its nutrition and active material.Want technical parameter：The intensity of pressure >=200Mpa；Water-bath
Temperature：4~8 DEG C；Treating capacity：5~10L/h.
Amnion emulsion of the present invention is prepared by super-pressure energy caused by equipment hydraulic power, material is passed through slit
Abrupt release, in the presence of shearing effect, void effect, material is set to reach shearing, homogeneous, scattered, emulsifying effectiveness, and keep
The stability of formulation, this method are pure physical method, do not destroy species activity and are added without any chemical substance.
3. filter amnion tissue homogenate through low-temperature ultrahigh-pressure continuous flow cell disintegrating machine processing after, then with 0.22 μm~
0.50 μm of membrane filtration is amnion emulsion.
4. Preserved amniotic emulsion preserves at 2~8 DEG C.
5. amnion quality of the emulsion is examined and presses amnion quality of the emulsion standard test, regulation should be met.The labeled of amnion emulsion
Active component is low peptide and free amino acid, and up-to-standard amnion emulsion content is respectively：Low peptide >=1mg/ml；Free amine group
Acid >=2mg/ml, character are milky translucent liquid, and pH value is 5.0~7.0, low peptide content is detected with Forint phenol method, per ml
≥1mg；2, free aminoacid content is detected with instrumental method, per ml >=2mg.
(2) prepared by amnion emulsion glue connection facial mask
Fibrin glued membrane is first prepared, then takes above-mentioned amnion emulsion to be uniformly applied on fibrin glued membrane, 15~20 DEG C
Avoid light place 30min.
(1) carry note thing and prepare and dissolve mammalian fibrinogen and fibrin ferment freeze-dried powder respectively, be made fibrinogen and
Fibrin ferment lysate, then fibrinogenolysis liquid is mixed (volume ratio 1 with fibrin ferment lysate：1) mix thoroughly, pour into mould into
Film, as fibrin glued membrane, ozonization is carried out to the fibrin glued membrane of formation, sterilize 60 under 10ppm concentration~
120min。
(2) amnion emulsion is uniformly applied to fibrin glued membrane one side by amnion emulsion coating, and coating layer thickness is no more than
0.1mm。
(3) the amnion emulsion and Fibrin Glue complex after temperature control solidification amnion emulsion coating, is placed in 15~20 DEG C of conditions
Lower solidification 30 minutes, as amnion emulsion glue connection facial mask.
(3) packaging and preservation
Vacuum sealed package is carried out to the amnion emulsion glue connection facial mask prepared, preserved at 2~8 DEG C, storage life 24
Individual month.
The foregoing is only a specific embodiment of the invention, but protection scope of the present invention is not limited thereto, any
Be familiar with those skilled in the art the invention discloses technical scope in, change or replacement can be readily occurred in, should all be covered
Within protection scope of the present invention.Therefore, protection scope of the present invention should be based on the protection scope of the described claims.
Claims (10)
1. a kind of amnion emulsion glue joins facial mask, it is characterised in that：The facial mask includes the facial mask made of fibrin glued membrane and carried
Patch thing and glue connection solidify carries the amnion emulsion on patch thing in the facial mask, and the amnion emulsion is that group is made in animal placenta amnion
Knit homogenate, the tissue emulsion for filtering form afterwards that the tissue homogenate is further degraded.
2. amnion emulsion glue according to claim 1 joins facial mask, it is characterised in that：The tissue homogenate is by tissue refiner
It is made, rotating speed >=12000rpm of tissue refiner when making tissue homogenate, the volume ratio of amnion and water for injection is 1：7 to 1：
11；Temperature environment is 15~20 DEG C.
3. amnion emulsion glue according to claim 1 joins facial mask, it is characterised in that：It is described to be degraded to using biomixer
The amnion cell in homogenate will be organized to be crushed, the biomixer is low-temperature ultrahigh-pressure continuous flow cell disintegrating machine, institute
State the intensity of pressure >=200Mpa of biomixer, bath temperature is 4~8 DEG C, treating capacity：5~10L/h.
4. amnion emulsion glue according to claim 1 joins facial mask, it is characterised in that：It is described to be cured as the amnion emulsion
It is placed under 15~20 DEG C of temperature conditionss and solidifies more than 30 minutes with Fibrin Glue film composite.
5. the amnion emulsion glue connection facial mask according to any one in Claims 1 to 4, it is characterised in that：The amnion breast
Low peptide content >=1mg/ml of liquid, free aminoacid content >=2mg/ml of the amnion emulsion, the pH value of the amnion emulsion
For 5.0~7.0.
6. a kind of method for the amnion emulsion glue connection facial mask being used to prepare as described in any one in Claims 1 to 5, its feature
It is：Methods described comprises the following steps：
(1) amnion emulsion is prepared：Specifically include following preparation process：(a) animal health inspection：Check, assess placental donor work
The health status of body, select healthy donors；(b) placenta is collected and cleaned：The placenta of selected healthy donors is collected, and to receiving
The placenta taken is cleaned；(c) amnion separation and processing：Amnion is separated from once purged placenta, by separated sheep
Film is shredded and cleaned；(d) amnion sterilizes：The amnion after shredding is sterilized using thimerosal；(e) prepared by amnion emulsion：Will be through
Amnion after sterilization is made tissue using tissue refiner and is homogenized, and tissue is homogenized and carries out clasmatosis, is handled through clasmatosis
It is filtered again afterwards to form amnion emulsion；
(2) prepare facial mask and carry patch thing：Solution fibrin original freeze-dried powder and fibrin ferment freeze-dried powder respectively, it is molten to be made fibrinogen
Liquid and thrombin solution, then fibrinogen solution and thrombin solution are uniformly mixed, formed after mixed solution solidification
Fibrin glued membrane；
(3) facial mask is prepared：The amnion emulsion prepared through step (1) is applied to the Fibrin Glue prepared through step (2)
Film surface, join facial mask by the amnion emulsion glue is formed after amnion emulsion and the solidification of Fibrin Glue film composite.
7. the method according to claim 6 for being used to prepare amnion emulsion glue connection facial mask, it is characterised in that：In the step
(e) when tissue homogenate is made in, rotating speed >=12000rpm of tissue refiner, the volume ratio of amnion and water for injection is 1：7 to
1：11；Temperature environment is 15~20 DEG C.
8. the method according to claim 6 for being used to prepare amnion emulsion glue connection facial mask, it is characterised in that：In the step
(e) amnion tissue homogenate addition low-temperature ultrahigh-pressure continuous flow cell disintegrating machine is dropped during the clasmatosis in
Solution, crushes amnion cell, the intensity of pressure >=200Mpa, the bath temperature of the biomixer are 4~8 DEG C, treating capacity：5
~10L/h.
9. the method for being used to prepare amnion emulsion glue connection facial mask according to any one in claim 6~8, its feature exist
In：Also include step (f) amnion quality of the emulsion after the step (e) to examine：The pH value of amnion emulsion, low peptide is examined to contain
Amount, free aminoacid content, pH value are that 5.0~7.0, low peptide content >=1mg/ml, free aminoacid content >=2mg/ml are
Qualified amnion emulsion.
10. the method according to claim 9 for being used to prepare amnion emulsion glue connection facial mask, it is characterised in that：With forint phenol
Method detects the low peptide content, and the free aminoacid content is detected with instrumental method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711088787.1A CN107595758A (en) | 2017-11-08 | 2017-11-08 | A kind of amnion emulsion preparation method, amnion emulsion glue connection facial mask and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711088787.1A CN107595758A (en) | 2017-11-08 | 2017-11-08 | A kind of amnion emulsion preparation method, amnion emulsion glue connection facial mask and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107595758A true CN107595758A (en) | 2018-01-19 |
Family
ID=61086207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711088787.1A Pending CN107595758A (en) | 2017-11-08 | 2017-11-08 | A kind of amnion emulsion preparation method, amnion emulsion glue connection facial mask and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107595758A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020157195A1 (en) * | 2019-01-30 | 2020-08-06 | Univerza V Ljubljani | Procedure for the preparation of an amniotic membrane homogenate based antimicrobial agent |
| CN113827539A (en) * | 2021-10-25 | 2021-12-24 | 广东普洛宇飞生物科技有限公司 | Multifunctional biological amnion mask and preparation method thereof |
-
2017
- 2017-11-08 CN CN201711088787.1A patent/CN107595758A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020157195A1 (en) * | 2019-01-30 | 2020-08-06 | Univerza V Ljubljani | Procedure for the preparation of an amniotic membrane homogenate based antimicrobial agent |
| CN113827539A (en) * | 2021-10-25 | 2021-12-24 | 广东普洛宇飞生物科技有限公司 | Multifunctional biological amnion mask and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884953B2 (en) | Method for preparing protein peptide based on connective tissue and prepared protein peptide and use thereof | |
| CN103079577B (en) | The preparation technology of wound restoration agent compositions, pipe and device | |
| KR20130060212A (en) | Dosage unit formulations of autologous dermal fibroblasts | |
| WO2014181886A1 (en) | Hybrid gel containing particulate decellularized tissue | |
| CN104055795B (en) | A kind of injectable implant and preparation method thereof | |
| CN109593124B (en) | Umbilical cord mesenchymal stem cell factor freeze-dried powder and preparation method thereof | |
| CN105056303A (en) | Composition, preparation and application thereof | |
| CN107034183A (en) | The method for preparing autologous fat stem cell bioactivity peptide freeze-dried powder | |
| CN106667899B (en) | Injectable hydrogels incorporating IGF-1C polypeptides | |
| CN108057116A (en) | Application of the stem cell composition in skin injury medicine | |
| CN109453200A (en) | The preparation method of mostly tissue-derived mescenchymal stem cell factor lytic freeze-dried powder | |
| CN107320768A (en) | Contain dressing of stem cell extract and preparation method thereof for wound repair | |
| CN108865986A (en) | For repairing articular cartilage damage/defect mescenchymal stem cell preparation and its preparation method and application | |
| CN111393521A (en) | Extraction method of jellyfish collagen | |
| CN105013014A (en) | Preparation method and application of acellular matrix biological material | |
| CN107550935A (en) | A kind of biological gel for treating joint disease and its application | |
| CN112870445A (en) | Preparation method and application of soft tissue repair material | |
| CN107595758A (en) | A kind of amnion emulsion preparation method, amnion emulsion glue connection facial mask and preparation method thereof | |
| CN108066750A (en) | Stem cell and its secretion are used to treat the new application of skin burn | |
| CN100581502C (en) | Human soft tissue filler for injection, and its preparation method | |
| Bhoopathy et al. | Haemostatic potency of sodium alginate/aloe vera/sericin composite scaffolds–preparation, characterisation, and evaluation | |
| CN107714609A (en) | A kind of amnion basement membrane, amnion facial mask based on amnion basement membrane and preparation method thereof | |
| CN108079363A (en) | A kind of kit and its application that cell processing is taken off for animal tissue | |
| CN108066824A (en) | A kind of new method for preparing skin blemish medicine | |
| CN107236032A (en) | A kind of method that multiple cytokine is extracted from umbilical cord tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180119 |
|
| WD01 | Invention patent application deemed withdrawn after publication |